Search

EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)

Dates: February 4-6, 2021

Chairs: H Einsele (EHA) & C Chabannon (EBMT)

For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…

Read more

EHA-IRSTH-IPHOS-SHRC Hematology Tutorial

 

         

In 2020 EHA will co-organize the 2nd Hematology Tutorial in Iran.

Read more

Call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition

Dear GoCART community,

With more than 5,000 CAR-T infusions registered in the EBMT Registry, EBMT and EHA are proud to announce the third call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition.

Read more

Precision Hematology

Definition: SWG-Precision Hematology focus on precision medicine for malignant hematology.

Read more

Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland

The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…

Read more

Nikolai Klimko 1956-2023

Professor Nikolai Klimko 

Professor Nikolai Klimko, MD PhD, FECMM
March 22, 1956 - March 30, 2023

With deepest sorrow we learned that on March 30, 2023, Professor Nikolai Nikolaevich Klimko passed at age 68.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

EHA-HKSH Hematology Tutorial on Lymphoid Malignancies

Dates: April 25-26, 2020 
Location: Hong Kong
Chairs: G Gaidano, J Gribben, MF Law

In 2020 EHA will co-organize the first Hematology Tutorial in Hong Kong, together with the Hong Kong Society of Haematology (HKSH).

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more